Abstract Photothermal therapy (PTT) for cancer treatment is the use of heat between 41 and 45°C to damage cancer cells. As a new type of transducer agent for PTT of cancer, CuS nanoparticles have several advantages. The most favorable features are the low cost, simple, and easy preparation and small size for targeting. However, the CuS nanoparticle PTT efficacy needs to be improved for practical applications. In this study, the CuS nano-PTT efficiency is enhanced via the local field enhancement from Ag nanoparticle surface plasmon coupling. The results show that absorbance of CuS nanoparticles in Ag/CuS nanocomposites is enhanced about four times by Ag nanoparticle surface plasmon coupling. Consequently, the PTT efficacy is enhanced and a power of 0.6 W/cm 2 with a 980-nm laser is sufficient for Ag/CuS nano-PTT activation for cancer treatment in vitro observations.
Introduction
Cancer remains one of the most deadly and challenging diseases in the world. In 2008, 7.6 million people died of cancer. Deaths from cancer worldwide are projected to continue rising, with an estimated 13.1 million deaths in 2030, according to the WHO Cancer Fact Sheet (http:// www.who.int/mediacentre/factsheets/fs297/en/index.html).
To fight the battle of cancer, more and better diagnostic and treatment modalities must be developed.
As a relatively noninvasive and gentle alternative for cancer treatment, hyperthermia is gaining increasing attention (Huang et al. 2006a; Huff et al. 2007) . Hyperthermia is commonly defined as heating tissue to a temperature in the range 41-45°C for tens of minutes (Svaasand et al. 1990; Zee 2002) . Tumors are selectively destroyed in this temperature range because of their reduced heat tolerance compared to normal tissue, which is due to their poor blood supply ). On one hand, hyperthermia can induce irreversible cell damage by loosening cell membranes and denaturing proteins (Huff et al. 2007; . On the other hand, as an adjuvant therapy with chemotherapy and radiotherapy, under mild temperature increases, hyperthermia can promote the development of both perfusion and reoxygenation in tumor tissues (Rau et al. 2000; Song et al. 1996) , thereby increasing the efficacy of chemotherapy and radiotherapy, respectively. Several methods have been developed for the delivery of thermal energy in a non-topical manner, such as microwave irradiation, radiofrequency pulses, and ultrasound. They can penetrate deep into tissue but may require a high fluence because of their diffuse nature, possibly producing undesirable hyperthermic effects in surrounding tissues (Li and Gu 2010) . Laser irradiation at near-infrared (NIR) frequencies can penetrate tissues with sufficient intensity and higher spatial precision for inducing localized hyperthermia (Castrén-Persons et al. 1991; Chen et al. 1997 ), but effective mechanisms are needed to transduce light energy into heat and to discriminate unhealthy from healthy cells (Huff et al. 2007) . One promising approach is to introduce the photothermal agents in the near-infrared region.
Photothermal therapies (PTT) for cancer have been widely investigated as a minimally invasive oncological treatment strategy in which photon energy is converted into heat to induce cellular destruction (O'Neal et al. 2004a; Rozanova and Zhang 2009; Huang and El-Sayed 2011) . With the tremendous development of nanotechnology, gold nanostructures such as nanospheres (El-Sayed et al. 2006; Khlebtsov et al. 2006) , nanorods (Dickerson et al. 2008; Huang et al. 2006b ), nanoshells (O'Neal et al. 2004b; Loo et al. 2005) , nanocages (Chen et al. 2005; Hu et al. 2006) , as well as carbon nanotubes Robinson et al. 2010 ) have been investigated extensively for PTT therapy in the near-infrared region. CuS nanoparticles have a broad absorption from 700 to 1,100 nm, and we first demonstrated that the interaction of CuS nanoparticles with near-infrared light can generate heat that can be harnessed for PTT of cancer cells Zhou et al. 2010) . As a new type of agent for photothermal treatment of cancer, CuS nanoparticles have several advantages such as the low cost, simple, and easy preparation and small size for targeting . However, the PTT efficiency using CuS nanoparticles as transducers is low and needs to be improved for practical applications (Tian et al. 2011; Lakshmanan et al. 2012) . Here, we investigate the enhancement of CuS nanoparticle PTT efficacy by Ag nanoparticle surface plasmon coupling in Ag/CuS nanocomposites for cancer treatment. A surface plasmon is a localized electromagnetic field at the metal dielectric interface (Englebienne et al. 2003) . Surface plasmons can lead to significant electric field enhancement near the surface and thus increase the rate of any processes that depend on the field intensity. The field enhancement due to surface plasmon resonance is predicted to be ∼1,000 times larger than the incident field and, therefore, it can be used to increase any light excitation or transition processes at the interfaces (Aslan et al. 2005; Lakowicz 2001 ). Because of the localized field amplification that occurs, excitation of surface plasmons in metal nanoparticles placed on a semiconductor might be expected to enhance optical absorption of incident photons within the semiconductor region near each nanoparticle. We have studied and observed the absorption enhancement of CuS by surface plasmon in Au/CuS nanocomposites and the application of Au/CuS for cancer treatment with improved efficacy (Lakshmanan et al. 2012) . Here, we report the observations on Ag/CuS nanocomposites for surface plamosn enhancement and the application for Ag/CuS nanocomposites for cancer treatment by in vitro studies. We are interested in Ag/CuS nanocomposites because it has been reported that among the three metals (Ag, Au, Cu) with efficient plasmon resonances, Ag exhibits the highest efficiency of plasmon excitation (Evanoff and Chumanov 2005) . Moreover, Ag is much cheaper than Au. Therefore, as photothermal transducer agents for cancer treatment, Ag/CuS nanocomposites might have a higher potential and better market than Au nanostructures and Au/CuS nanocomposites. 
Preparation of Ag nanoparticles
Ag nanoparticles were grown using the seeded growth method according to the literature (Sun et al. 2009 ). Specifically, the seeds were made by the addition of a freshly prepared, ice-cold 0.01 M NaBH 4 solution (600 μL, 0.006 mmol) into a mixture solution composed of 0.01 M AgClO 4 (250 μL, 0.0025 mmol) and 0.1 M CTAB (7.5 mL, 0.75 mmol). The resultant solution was mixed by rapid inversion for 2 min and was then kept at room temperature for 1 h before use. The growth solution was prepared by the sequential addition of 0.1 M CTAB (6.4 mL, 0.64 mmol), 0.01 M AgClO 4 (800 μL, 0.008 mmol), and 0.1 M ascorbic acid (3.8 mL, 0.38 mmol) into water (32 mL). The CTAB-stabilized seed solution was diluted ten times with water. The diluted seed solution was then added into the growth solution for the growth of Ag nanoparticles. The resultant solution was mixed by gentle inversion for 10 s and then left undisturbed overnight.
Synthesis of Ag/CuS nanocomposites
Nickel thiobenzoate ((PhCOS) 2 Ni) is used as the sulfur source for Ag/CuS synthesis and is synthesized based on the synthetic route reported in the literature (Sun et al. 2009 ). Sodium thiobenzoate was first prepared by mixing together Na 2 CO 3 (211.98 mg, 2.00 mmol), thiobenzoic acid (PhCOSH, 520 μL, 4.40 mmol), and water (1 mL) at room temperature. The resultant concentrated PhCOSNa solution was then added into an aqueous 0.4 M Ni(NO 3 ) 2 (10 mL, 2.00 mmol) solution to produce nickel thiobenzoate ((PhCOS) 2 Ni). The dark red precipitate was washed with water and dried under ambient conditions.
To prepare Ag/CuS nanocomposites, (PhCOS) 2 Ni (2 mg, 0.006 mmol) was dissolved in the Ag nanoparticle dispersion (10 mL), followed by the addition of 0.01 M Cu(NO 3 ) 2 solution. The concentration of Cu 2+ in the solution was controlled to be 300 μM. The resultant mixture solution was transferred into an autoclave and heated at 140°C for 3 h, and then cooled down to room temperature. The prepared nanoparticle solution was dialyzed for 3 h to remove all the unreacted chemicals.
Preparation of CuS nanoparticles
CuS nanoparticles were prepared as follows: to 100 mL of an aqueous solution containing CuCl 2 (0.1 mmol, 17.05 mg) and sodium citrate (0.068 mmol, 20 mg), 1 mL of sodium sulfide solution (Na 2 S, 0.1 M) was added while stirring at room temperature. The pale blue CuCl 2 solution turned dark brown immediately upon the addition of sodium sulfide. After 5 min, the reaction mixture was heated to 90°C and stirred for 15 min, until dark green solution was obtained. The citrate-coated CuS nanoparticles were obtained and stored at 4°C.
Characterization of Ag/CuS nanocomposites
Ag/CuS nanocomposites in solution were placed onto holey carbon-covered copper grids for high-resolution transmission electron microscope (HRTEM) observation. The HRTEM images of the particles were obtained with a JEOL JEM-2100 electron microscope (Tokyo, Japan) with accelerating voltage of 200 kV. The absorption spectra were recorded using a Shimadzu UV-2450 UV-Vis spectrophotometer (Kyoto, Japan). The luminescence excitation and emission spectra were measured using a Shimadzu RF-5301PC fluorescence spectrophotometer (Kyoto, Japan). The Ag and Cu element analysis were operated on the PerkinElmer ELAN DRC II ICP Mass Spectrometer system (ICP-MS) with an autosampler.
Photothermal effect in aqueous solution
For measuring temperature change mediated by CuS nanoparticles or Ag/CuS nanocomposites, 980 nm nearinfrared light (Opto Engine LLC) at an output power of 0.6 W/cm 2 was delivered through a cuvette containing the nanoparticles (1 mL). The Cu concentration in both Ag/CuS nanocomposites and CuS nanoparticles was 13.912 mg/L. The temperature was measured by a digital thermometer (Fisher Scientific "Traceable") over a period of 20 min. Water was used as a control.
In vitro fluorescence imaging
In this study, prostate cancer PC-3 cells were used to evaluate the fluorescence imaging of Ag/CuS nanocomposites. PC-3 were cultured in F-12K medium supplemented with 10 % fetal bovine serum and 1 % penicillin-streptomycin solution, and incubated at 37°C in a water-saturated incubator with 5 % CO 2 . The cells were treated with 10 % of original Ag/CuS nanocomposites for 24 h. The Ag and Cu concentration of original Ag/CuS nanoparticles were 46.606 and 13.912 mg/L, respectively. Fluorescence imaging was done on the following day using an Olympus 1X71 inverted fluorescence microscope.
Time course of cellular uptake by PC-3 cells
The time course of cellular uptake was also carried out on prostate cancer PC-3 cells. Aliquots of the cultured cells w e r e i n c u b a t e d w i t h 5 % o f o r i g i n a l A g / C u S nanocomposites for 10 min, 30 min, 1 h, 2 h, 4 h, and 8 h at 37°C under 5 % CO 2 in the 1.5 mL centrifuge tubes. After incubation, the cells were washed two times with PBS. All the imaging results were examined by an Olympus 1X71 Inverted Microscope (Tokyo, Japan).
In vitro photothermal ablation of cancer cells with Ag/CuS nanocomposites
The cells were cultured as described in the above section and incubated with 2.5, 5, and 10 % of the original Ag/CuS nanoparticle solution at 37°C and 5 % CO 2 for 4 h. After incubation was completed, the culture medium with nanoparticles were removed and resupplied with fresh medium. The cells were then irradiated with a 980-nm NIR laser (Opto Engine LLC) at an output power of 0, 0.6, 1.2, or 1.8 W/cm 2 for 5 min. Fluorescence imaging was used to see the number of living and dead cells after photothermal 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) assay was also applied to estimate the photothermal effect of Ag/CuS nanocomposites. The cultured PC-3 cells were incubated with 5 and 10 % of original Ag/CuS nanocomposites for 4 h and were irradiated with a 980-nm NIR laser (Opto Engine LLC) at an output power of 0, 0.3, 0.6, or 0.9 W/cm 2 for 1 min. Ten microliters of 5 mg/ml MTT solution was added to each well and incubated for 4 h at 37°C under 5 % CO 2 . The supernatant was then removed, and the cells were lysed with 50 μL dimethyl sulfoxide. Using a microplate reader, absorbance was recorded at 570 nm to determine cell survival.
Results and discussion
The morphology of Ag/CuS nanocomposites was observed by the HRTEM as shown in Fig. 1 Sohrabnezhad and Pourahmad 2012) , while the broad absorption around 914 nm in Ag/CuS nanocomposites and CuS nanoparticles is assigned to CuS absorption Zhou et al. 2010; Tian et al. 2011; Lakshmanan et al. 2012) . For the mixture of Ag and CuS nanoparticles, no enhancement was observed on the absorption of CuS nanoparticles. However, the CuS absorbance at 914 nm is enhanced almost four times in Ag/CuS nanocomposites when the Cu concentration of CuS nanoparticles and Ag/CuS nanocomposites are the same. Similar to what observed in Au/CuS nanocomposites (Lakshmanan et al. 2012) , the enhancement of CuS absorption in Ag/CuS is due to the coupling of Ag nanoparticle surface plasmon with the d-d transition of Cu 2+ in CuS nanoparticles. However, the enhancement of CuS absorption in the Ag/CuS nanocomposites is higher than the plasmon enhancement by Au (2.2 times) in the Au/CuS nanocomposites (Lakshmanan et al. 2012) . The TEM images also show that Ag and CuS nanoparticles are closely packed together in the nanoparticles which enable their coupling to cause the enhancement. The local field enhanced absorption intensity in Ag/CuS nanocomposites may enhance the PTT efficacy. To prove the enhancement, the photothermal effect in the aqueous solution was measured upon exposure to 980-nm NIR laser (Opto Engine LLC). Generally, the NIR region of the spectrum provides maximal penetration of light due to relatively lower scattering and absorption from the intrinsic tissue chromophores. More importantly, the conservative limit of 980-nm laser intensity set for human skin exposure is ∼0.726 W/cm 2 , which is more than two times of that (∼0.33 W/cm 2 ) of the 808-nm laser (Tian et al. 2011 ). Therefore, in our experiments, the observations were conducted on a 1-mL solution irradiated by a 980-nm NIR laser at an output power of 0.6 W/cm 2 . As shown in Fig. 3 , with the extension of irradiated time, the temperature increases gradually. After 12-min irradiation, the temperature was enhanced 3.7°C by Ag/CuS nanocomposites while the temperature was only enhanced 1.4°C by CuS nanoparticles. In the same period of irradiated time, Ag/CuS always arrives in higher temperature than CuS nanoparticles.
Figures 4 and 5 show fluorescence properties of Ag/CuS nanocomposites and L-ascorbic acid, respectively. Through and 5a, the broad blue-green luminescence peaking at 450 nm is actually derived from the stabilizer ascorbic acid (Guilbault 1990; Wintzinger et al. 2010) . Otherwise, in order to further prove the luminescent properties of L-ascorbic acid, the relationship between the emission intensity and the concentration of ascorbic acid is investigated in Fig. 5b, c . The results demonstrate the linear relationship between the emission intensity and the concentration of ascorbic acid. With the concentration of L-ascorbic acid increase, the emission intensity rises. Thus, we infer that L-ascorbic acid indeed has photoluminescence which can be used for cell imaging. Figure 6 shows the uptake of Ag/CuS nanocomposites by PC-3 prostate cancer cells after 24-h incubation. The nucleus of cells was stained with a blue emission dye DAPI. The results show that Ag/CuS nanocomposites can get into PC-3 cells and mainly locate in their cytoplasm. To further observe the cell uptake of these nanocomposites, images were taken for the PC-3 cells treated with Ag/CuS nanocomposites for 10, 30 min, and 1, 2, 3, 4 and 8 h, respectively. The results are shown in Fig. 7 . No bright green luminescence is observed in the cells after the incubation less than 1 h. Only after 2-h incubation, luminescence imaging shows that the particles were taken by the cells. As time increasing, the uptake and luminescence intensity are increased and reach the brightest at the 4 h of incubation which means that the cell uptake is saturated. After 8-h incubation, the luminescence is decreased in intensity. This could be due to the loss of the nanocomposites from the cells or the quenching of the ascorbic acid luminescence by the cells. Thus, we may conclude that 4-h incubation is good for cell uptake and treatment. Figure 8 shows the results of photothermal treatments on PC-3 cells with 980-nm laser at 0.6 W/cm 2 for 5 min. Calcein AM is used for visualization of live cells and EthD-1 is for visualization of dead cells. As seen, without nanocomposites all the cells can survive under the laser treatment, while the combination of the laser and the nanocomposites can effectively kill the cancer cells. More and more cells died with the increase of the concentration of nanocomposites at the same laser power and treatment duration. Considering the effective treatment for cancer cells using Ag/CuS nanocomposites dependent on the concentration of nanocomposites, laser power, and treatment duration, the results of the treatment on PC-3 cells at the concentration of 5 % of original Ag/CuS nanocomposites upon the exposure to laser power of 0, 0.6, 1.2, and 1.8 W/cm 2 are also carried out in Fig. 9 . Without laser, all the cells are alive. More cells were destroyed at the higher laser powers with the same concentration of nanocomposites and treatment duration. Thus, it is concluded that no cancer cells die treated with nanocomposites or laser alone. Only the combination of nanocomposites and laser can kill the cells. The increase of the concentration of Ag/CuS nanocomposites and laser power can induce more cells to die. Here, we have to illustrate the reason why the morphology of the cells in Figs. 6, 7, 8 , and 9 look different. In the cell imaging experiment, in order to locate the Ag/CuS nanocomposites in the cells, the cells should be fixed at the bottom of the cell culture plate. However, considering the possibility of the physical adhesion of Ag/CuS nanocomposites to the culture plate to interfere with the experimental results, the cell cultivation method using EP tubes are utilized in the time course cell uptake. This method is very convenient to use centrifugation to remove all the free particles. However, the disadvantage is to miss the observation of the morphology of cells. While in the photothermal ablation experiments, in order to observe more cells, the biggest scale 100 μm is used rather than 50 μm as before. Thus, due to the different methods and different scales, the morphology of the cells look different. A quantitative study on the photothermal effect of Ag/CuS nanocomposites was carried out using MTT assay (Fig. 10) for laser output powers of 0, 0.3, 0.6, and 0.9 W/cm 2 and nanoparticle concentrations of 5 and 10 %. As a control, the normal cells without nanoparticle and laser treatment represent 100 % viability. The cells treated with lower concentration of Ag/CuS nanocomposites (5 %) have higher viability than those with higher concentration (10 %). With the increase of the laser power, the viability of cells decreases. Without the laser treatment, some cells still died to some extent. It is perhaps due to the existence of CTAB in the nanocomposites (Alkilany and Murphy 2010; Murphy et al. 2008) , even though we try to remove all the CTAB using dialysis method.
Conclusion
Surface plasmon-enhanced photothermal therapy for cancer treatment was investigated in vitro on PC-3 prostate cancer cells using Ag/CuS nanocomposites. The diameters of the Ag/CuS nanocomposites are in the range of 10-20 nm and they have a high absorbance in the near-infrared region. Ag/CuS nanocomposites can get into PC-3 cancer cells and mainly locate in the cytoplasm. The treatment observations found that 5 % of original Ag/CuS nanocomposites activated by a 980 nm laser at 0.6 W/cm 2 can efficiently kill cancer cells. With the increase of the nanocomposite concentration or the laser output, more and more cells were killed. Comparing with CuS nanoparticles, surface plasmon-enhanced Ag/CuS nanocomposites have a higher efficiency for the photothermal therapy. It is also a new and promising modality for cancer treatment.
